#Neurological Disorders

Circular Genomics Secures $15 Million Series A for Alzheimer's Blood Test

NRG Therapeutics Secures £50M Series B for ALS, Parkinson's Drugs

NRG Therapeutics secured £50 million in Series B funding, led by SV Health Investors’ Dementia Discovery Fund. This investment will advance mitochondrial-targeting treatments for neurodegenerative diseases. The company aims to transition its pipeline, including lead candidate NRG5051 for ALS and Parkinson's, into...

Neuralink Secures Massive $650M Series E Funding